A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Trametinib (Primary)
- Indications Brain metastases
- Focus Adverse reactions; Pharmacokinetics
- 10 Oct 2024 Planned End Date changed from 27 Sep 2024 to 8 Oct 2025.
- 01 May 2022 Status changed from active, no longer recruiting to discontinued as per results published in the Radiotherapy and Oncology
- 01 May 2022 Results published in the Radiotherapy and Oncology